Spantide I|cas:91224-37-2|西域试剂

Spantide I,98.97%

产品编号：Bellancom-P1194| CAS NO：91224-37-2| 分子式：C₇₅H₁₀₈N₂₀O₁₃| 分子量：1497.79

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P1194	￥1400.00	杭州北京（现货）
Bellancom-P1194	￥3800.00	杭州北京（现货）
Bellancom-P1194	￥6100.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Spantide I

产品介绍

Spantide I 是substance P 的类似物，是选择性的神经激肽-1 受体 (NK₁ receptor) 的拮抗剂，其对NK₁ 和 NK₂ 受体的 K_i 值分别为 230 nM 和 8150 nM。Spantide I 可减少感染角膜的1型细胞因子和增强2型细胞因子 IL-10，从而显著减少角膜穿孔。

生物活性

Spantide I, a substance P analog, is a selective NK₁ receptor antagonist, with K_i values of 230 nM and 8150 nM for NK₁ and NK₂ receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation.

体外研究

体内研究

Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals.
Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNA levels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female, 8-week-old C57BL/6 (B6) and BALB/c mice.
Dosage:	36 μg/mouse.
Administration:	IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection).
Result:	At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice. Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi. Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi. Significantly reduced the level of IL-18 mRNA at 1 day pi.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female, 8-week-old C57BL/6 (B6) and BALB/c mice.
Dosage:	36 μg/mouse.
Administration:	IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection).
Result:	At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice. Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi. Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi. Significantly reduced the level of IL-18 mRNA at 1 day pi.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (66.77 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.6677 mL	3.3383 mL	6.6765 mL
5 mM	0.1335 mL	0.6677 mL	1.3353 mL
10 mM	0.0668 mL	0.3338 mL	0.6677 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture